United Therapeutics has filed a patent for a method of treating pulmonary hypertension by administering a combination of iloprost and treprostinil through inhalation. The treatment aims to provide relief for patients suffering from this disease. GlobalData’s report on United Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on United Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. United Therapeutics's grant share as of September 2023 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of pulmonary hypertension by inhalation of iloprost and treprostinil
A recently filed patent (Publication Number: US20230263807A1) describes a method for treating pulmonary hypertension using a combination of iloprost and treprostinil administered through inhalation. Pulmonary hypertension is a condition characterized by high blood pressure in the arteries of the lungs, leading to various complications.
The patent claims that the method involves administering iloprost or a pharmaceutically acceptable salt thereof, along with treprostinil or a pharmaceutically acceptable salt thereof, to a subject in need of treatment. The dosage of iloprost delivered should be at least 2.5 µg, while the dosage of treprostinil should be at least 5 µg.
The patent also describes a pharmaceutical formulation comprising iloprost and treprostinil, which can be in the form of a liquid or an inhalable formulation. The concentration of iloprost in the formulation can range from 5 µg/ml to 50 µg/ml, while the concentration of treprostinil can range from 200 µg/ml to 2000 µg/ml. The formulation may also include a buffer, such as sodium phosphate buffer, and a salt, such as sodium chloride. It is important for the formulation to be isotonic, with a pH ranging from about 6.0 to 7.0, and an osmolality ranging from 250 mOsm/kg to 400 mOsm/kg.
The patent further claims that the pharmaceutical formulation can be used to treat pulmonary hypertension by administering it through inhalation. The method involves preparing the formulation, storing it for at least one month, and then administering it to the subject. The patent emphasizes that the amount of iloprost in the formulation should remain at least 90% of the initial amount after the storage period.
In summary, this patent describes a method and pharmaceutical formulation for treating pulmonary hypertension using a combination of iloprost and treprostinil administered through inhalation. The patent highlights specific dosage requirements, formulation characteristics, and storage considerations to ensure the effectiveness of the treatment.
To know more about GlobalData’s detailed insights on United Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
